ADAGIO THERAPEUTICS INC (ADGI)
US00534A1025 - Common Stock
ADAGIO THERAPEUTICS INC
NASDAQ:ADGI (9/12/2022, 7:13:11 PM)
After market: 4.52 -0.12 (-2.59%)4.64
+0.04 (+0.87%)
Company Profile
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is headquartered in Waltham, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2021-08-06. The firm is focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. Its product candidate, adintrevimab, for the prevention and treatment of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. The firm has a clinical program with a Phase I healthy volunteer single ascending-dose escalation study to establish the safety, pharmacokinetics, and serum virus neutralizing antibody titers of adintrevimab. Its Phase II/III global clinical trial, EVADE, evaluates adintrevimab in the prevention of symptomatic COVID-19 in two separate populations: individuals with known exposure to a person with laboratory-confirmed SARS-CoV-2 infection, also known as post-exposure prophylaxis, and individuals who are at increased risk for SARS-CoV-2 infection, also known as pre-exposure prophylaxis.
Company Info
ADAGIO THERAPEUTICS INC
1601 Trapelo Road, Suite 178
Waltham MASSACHUSETTS
P: 17818190080.0
Employees: 101
Website: https://adagiotx.com/
ADGI News
a year ago - The Rosen Law Firm PAIVVD FINAL DEADLINE MONDAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IVVD, ADGI
a year ago - Kahn Swick & Foti, LLCINVIVYD SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI
a year ago - Rosen Law FirmNATIONALLY RANKED ROSEN LAW FIRM Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IVVD, ADGI
a year ago - InvivydInvivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshopa year ago - InvivydInvivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical OfficerIntegrated discovery platform is producing a stream of candidate antibodies demonstrating broad in vitro neutralization against past variants of concern...
ADGI Twits
Here you can normally see the latest stock twits on ADGI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
